Drugs / Engerix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT04870021 | Mar → Nov 2015 | hepatitis B virus infection | Quaid-e-Azam University | Completed | Met primary |
| Phase 4 | NCT00240526 | Oct 2003 → Mar 2010 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00839254 Comparator | Feb 2009 → Jan 2012 | pneumococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00637195 Background | Mar → Jun 2008 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Engerix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00240526 ↗ |
| Known as | Engerix -B | “Biological: Engerix™ -B” NCT00240526 ↗ |
| Modality | Vaccine | “Hepatitis B (Engerix™) vaccine” NCT00637195 ↗ |
| Route | Intramuscular | “Intramuscular administration, 4 doses.” NCT00637195 ↗ |